GERD study: Domperidone
Official title Compassionate Use of Domperidone for Refractory Gastroparesis
ClinicalTrials.gov ID: NCT04699591
What this study is testing
What is Domperidone?
an investigational oral medicine being studied as a potential treatment for gastroesophageal reflux disease (GERD) in children and adolescents is designed to block dopamine receptors in the gut, which can increase gastrointestinal motility and help move stomach contents more quickly
Also referred to as Motilium, Motillium, Motinorm Costi, Nomit, Brulium, Molax.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is testing whether domperidone helps children and young adults with gastroparesis or GERD who have tried all standard treatments.
- Who it's for
- You may be able to join if you are 12 to 21 years old, have gastroparesis or GERD, and have not improved with usual medicines.
- What's involved
- You would take domperidone, a medicine that helps the stomach move food. You would follow the doctor’s instructions for the medicine.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 12 to 21
You may be able to join if
- Male or female
- Age 12 - 21
- Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms)...
- Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
- increased prolactin levels
You likely can't join if
- History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes.
- Clinically significant bradycardia, sinus node dysfunction, or heart block.
- Clinically significant electrolyte disorders.
- Gastrointestinal hemorrhage or obstruction
- Presence of a prolactinoma (prolactin-releasing pituitary tumor).
- Pregnant or breast feeding female
See the full eligibility criteria
- Male or female
- Age 12 - 21
- Symptoms or manifestations secondary to GERD (e.g., persistent esophagitis, heartburn, upper airway signs or symptoms or respiratory symptoms), gastrointestinal motility disorders such as nausea, vomiting, severe...
- Patients must have a comprehensive evaluation to eliminate other causes of their symptoms.
- increased prolactin levels
- extrapyramidal side effects
- breast changes
- Cardiac arrhythmias including QT prolongation
- There is a potential for increased risk of adverse events with the drugs and herbal supplements listed in the addendum (See Addendum on pages 24 and 25)
- The coordinator/investigator will have a discussion with the family about the use of any of the medications and herbal supplements listed in the addendum to make sure they understand the increased risk of their use and...
- History of, or current, arrhythmias including ventricular tachycardia, ventricular fibrillation and Torsade des Pointes. Patients with minor forms of ectopy (PACs) are not necessarily excluded.
- Clinically significant bradycardia, sinus node dysfunction, or heart block. Prolonged Tc (QTc\> 450 milliseconds for males, QTc\>470 milliseconds for females).
- Clinically significant electrolyte disorders.
- Gastrointestinal hemorrhage or obstruction
- Presence of a prolactinoma (prolactin-releasing pituitary tumor).
- Pregnant or breast feeding female
- Known allergy to domperidone
The study team makes the final eligibility decision.
Where it is enrolling
- Kansas City, Missouri, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 12 years to 21 years. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Kansas City, Missouri, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.